Meta Information

ID:bexagliflozin

Name:Bexagliflozin

Schema Version:1.5

Alternate Names

• Brenzavvy

Active Compound

bexagliflozin

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:rx_drug

Indication

Focus:

disease_treatment

Description:

To improve glycemic control in adults with type 2 diabetes mellitus.

Typical Protocol

• The standard clinical dose is 20 mg taken orally once daily in the morning.

Expected Cost Mean

Low Cost:

50

High Cost:

550

Cost Type:

monthly

Description:

Monthly cost for daily tablets; often covered by insurance for indicated use.

Summary

Bexagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, which causes excess glucose to be excreted in the urine. This mechanism effectively lowers blood sugar levels and has shown secondary benefits for cardiovascular and renal health in diabetic populations.

Purpose

Lowers blood glucose by promoting its excretion in urine.

Card Summary

An SGLT2 inhibitor drug that lowers blood sugar for type 2 diabetes.

Drug Class

sglt2_inhibitor

Drugs In Class

Empty Array

Impact

Score:

7.8

Justification:

Highly effective for glycemic control with proven cardiovascular and renal benefits in diabetics.

Evidence

Grade:

A

Score:

9.5

Justification:

Extensive, large-scale human randomized controlled trials for its approved indication.

Safety

Score:

5.5

Justification:

Known risks include genital/urinary infections and rare but serious ketoacidosis or gangrene.

Flags

• Increased risk of genital mycotic infections (yeast infections) and urinary tract infections.
• Risk of dehydration and hypotension, especially when combined with diuretics or in the elderly.
• Rare but serious risk of diabetic ketoacidosis (DKA), even with near-normal blood glucose.
• Associated with a rare but life-threatening bacterial infection of the perineum (Fournier's gangrene).
• Not recommended for patients with severe renal impairment (e.g., eGFR < 30).

Verdict

Effective for T2D glycemic control under strict medical supervision.

Created

2026-04-30T23:29:00.381304Z

Ai Model

Gemini 2.5 Pro (High)